AI Clinical Trial Imaging segmentation by application distinguishes four primary clinical domains—Oncology Imaging, Neurology Imaging, Cardiology Imaging, and Orthopedic Imaging—plus an “Other” catch‑all. Oncology Imaging, encompassing tumor detection, response assessment, and biomarker quantification, accounts for roughly 35 % of total market revenue because oncology trials generate the highest imaging volume and demand for AI‑driven volumetric analysis. Neurology Imaging, covering neurodegenerative disease trials, stroke, and functional MRI assessments, contributes about 25 % as trial protocols increasingly rely on automated lesion segmentation and connectivity mapping. Cardiology Imaging, which includes coronary CT, echocardiography, and cardiac MRI analyses, represents near 20 % of the market, driven by growing cardiovascular trial pipelines and the need for rapid, reproducible measurements of ejection fraction and plaque burden. Orthopedic Imaging, focused on joint degeneration and fracture healing studies, supplies roughly 15 % of revenue, reflecting moderate trial activity but high value placed on AI‑assisted alignment and bone density quantification. The residual 5 % “Other” aggregates niche areas such as pulmonary and gastrointestinal imaging, each contributing marginally. This application‑based taxonomy clarifies the relative weight of each segment within the AI Clinical Trial Imaging market.